Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.31 |
| ▸ | GPR183 | P32249 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988153 | 1.00 | GRIA2 (0.43) | GRIA2SCN9AXDHGRM5HDAC1 | |
| SCHEMBL12987372 | 0.90 | GRIA2 (0.46) | GRIA2SCN9AXDHGRM5HDAC1 | |
| SCHEMBL15441136 | 0.90 | GRIA2 (0.46) | GRIA2SCN9AXDHGRM5HDAC1 | |
| SCHEMBL15441034 | 0.89 | GRIA2 (0.46) | GRIA2XDHGRM5HDAC1HDAC2 | |
| SCHEMBL12987133 | 0.89 | GRIA2 (0.46) | GRIA2XDHGRM5HDAC1HDAC2 | |
| SCHEMBL15420266 | 0.88 | KDM4E (0.41) | GRIA2XDH | |
| SCHEMBL12987294 | 0.87 | GRIA2 (0.39) | GRIA2SCN9AHDAC1HDAC2GRM4 | |
| SCHEMBL15420174 | 0.87 | GRIA2 (0.39) | GRIA2SCN9AHDAC1HDAC2GRM4 | |
| SCHEMBL12987095 | 0.87 | GRIA2 (0.39) | GRIA2SCN9AHDAC1HDAC2GRM4 | |
| SCHEMBL15441453 | 0.87 | GRM5 (0.35) | GRIA2SCN9AGRM5GRM4AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | GRIA2 12/4885SCN9A 648/4885XDH 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.